Alpha-fetoprotein (AFP) testing, integrated within the Helthesh system, is a diagnostic procedure used to assess various medical conditions, particularly those related to cancer and fetal development. AFP is a protein primarily produced by the liver of a developing fetus, and its levels in the blood can be indicative of certain health conditions.

In the context of cancer diagnosis, AFP testing is commonly used as a tumor marker, particularly for liver cancer (hepatocellular carcinoma) and germ cell tumors such as testicular cancer or ovarian cancer. Elevated AFP levels in the blood may suggest the presence of these cancers, although further diagnostic tests are usually necessary to confirm the diagnosis.

Additionally, AFP testing is sometimes utilized in prenatal screening to evaluate the risk of certain fetal abnormalities, including neural tube defects or chromosomal abnormalities. However, it’s important to note that AFP testing alone is not considered a definitive diagnostic tool for these conditions, and additional testing may be required.

Integrating AFP testing within the Helthesh system allows for streamlined and comprehensive analysis, facilitating accurate diagnosis and timely intervention in various medical contexts. This innovative approach enhances healthcare providers’ ability to make informed decisions and provide personalized care to patients.